AstraZeneca Asthma Drug Fails COPD Study for a Second Time

AstraZeneca Plc’s Fasenra failed to meet its goal in a late-stage trial of patients with chronic obstructive pulmonary disease for a second time, a blow to the drugmaker’s efforts to expand the market for the asthma treatment....

Redirecting to full article...